It should also be noted that for this analysis, MTX use was defined as co-prescription at the time of commencement of an anti-TNF (i.e. baseline entry to the BSRBR-RA), not at subsequent follow-up visits. The gene discussed is TNF; the disease is rheumatoid arthritis.